Use of the Activating Gene Mutation of the Tyrosine Kinase (VAL617Phe) JAK2 as a Minimal Residual Disease Marker in Patients With Myelofibrosis and Myeloid Metaplasia After Allogeneic Stem Cell Transplantation-Reference-Cited by-同舟云学术

Use of the Activating Gene Mutation of the Tyrosine Kinase (VAL617Phe) JAK2 as a Minimal Residual Disease Marker in Patients With Myelofibrosis and Myeloid Metaplasia After Allogeneic Stem Cell Transplantation

Published:2007-06-15 Issue:11 Volume:83 Page:1518-1520
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Steckel Nina K.,Koldehoff Michael,Ditschkowski Markus,Beelen Dietrich W.,Elmaagacli Ahmet H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference5 articles.

1. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.;Baxter;Lancet,2005

2. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.;Levine;Cancer Cell,2005

3. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphoccytic leukemia.;Levine;Blood,2005

4. Mutations in innate immune system NOD2/CARD15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host-disease in patients who underwent an allogeneic transplantation.;Elmaagacli;Transplantation,2006

5. Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation.;Elmaagacli;Int J Hematol,2002

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation;Haematologica;2019-07-11

2. Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches;BioMed Research International;2016

3. When and how to transplant patients with myelofibrosis;Novel Insights into Myelofibrosis Pathophysiology and Treatment;2015-05

4. Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation ofJAK2V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation;Case Reports in Hematology;2015

5. Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies;Frontiers in Oncology;2014-08-08